At a Glance
Polaris Partners is a leading early-stage venture capital firm founded in 1996, with deep roots in Boston's biotech and technology ecosystem. The firm manages over $6 billion in assets under management across multiple funds, focusing primarily on healthcare and life sciences investments while also backing enterprise technology companies. Polaris has built a reputation as one of the premier life sciences investors, with a team that includes experienced entrepreneurs, former executives, and scientists who bring operational expertise to their portfolio companies. The firm is known for its hands-on approach, often working closely with management teams to build category-defining companies from the ground up. Notable successful investments include Foundation Medicine, which was acquired by Roche for $2.4 billion, and Blueprint Medicines, which went public and achieved significant market capitalization. The firm typically invests in Series A and Series B rounds, taking board seats and providing strategic guidance to help companies navigate the complex regulatory and commercial challenges in healthcare and technology markets.
“Invests in healthcare and technology companies with differentiated approaches to large market opportunities, from seed to growth.”
Polaris Partners primarily invests at the Seed, Series A, Series B+ stages. This means they focus on companies that are building their initial product and finding product-market fit.
Polaris Partners is headquartered in Boston, MA. Many of their portfolio companies are also based in this region, though they invest across geographies.
Polaris Partners focuses on investments in Biotech, Digital Health, Enterprise, SaaS. Their portfolio reflects deep expertise and networks within these sectors.
Polaris Partners's typical investment check size ranges from $1M to $50M. Actual amounts may vary based on the stage, sector, and specific opportunity.
Polaris Partners manages approximately $6B in assets under management (AUM) across their funds.